Filed in archive
Corporate and Industrial News
, Drugs, Vaccines and Therapeutics
, Patents and Intellectual Property Rights
by ruth on April 12, 2006

its pegylated version of EPO does not infringe Amgen's patents because it is linked to a chemical that makes it last longer in the body than Epogen, which Amgen sells in the United States as a treatment for anemia in patients on kidney dialysis.
According to a Reuters article, Roche's Cera has not yet been approved for sale in the US or in Europe. Amgen is hopeful that the ITC will launch a formal investigation which might take months to complete, considering that Amgen is seeking a "permanent exclusion order." Meanwhile, Roche will continue to file marketing applications worldwide.
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/19963
Mr Wong
Vote for Amgen Seeks Banning of Roche's Anemia Drug, Cera:
|
Rating: 5.67 out of 6 vote(s) cast.
|
Subscribe
Use the search to look for other interesting posts
| RSS | See all blog subscribe options |
|
What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |







